Literature DB >> 1987863

High-grade dysplasia in the columnar-lined esophagus.

N K Altorki1, M Sunagawa, A G Little, D B Skinner.   

Abstract

Abnormal columnar lining of the esophagus is a well-recognized premalignant condition. The management of patients with high-grade dysplasia without evidence of carcinoma remains controversial. Esophagectomy is proposed by some investigators, whereas others favor follow-up endoscopy and biopsy until microinvasive malignancy is documented. We reviewed our experience with nine patients referred with high-grade dysplasia on endoscopic biopsies without evidence of carcinoma. Eight patients had the columnar lining extending orad from the cardia, and one patient had heterotopic columnar epithelium in the cervical esophagus. All were white men ranging in age from 19 to 76 years (median: 47 years). Eight patients underwent esophagectomy with colon interposition. A sleeve resection of the cervical esophagus was done in one patient. Multifocal carcinoma was found in three patients, all of whom had severe dysplastic changes throughout the columnar lining. The patient with heterotopic columnar epithelium had microinvasive carcinoma. All four patients with carcinoma had negative nodes and are long-term survivors. No carcinoma was found in the resected specimens of the remaining five patients. High-grade dysplasia is an important marker of malignancy in patients with a columnar-lined esophagus. Esophagectomy is indicated in suitable candidates since carcinoma was found in 45% of our patients.

Entities:  

Mesh:

Year:  1991        PMID: 1987863     DOI: 10.1016/0002-9610(91)90367-m

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  25 in total

Review 1.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 2.  High-grade dysplasia in Barrett's esophagus: surveillance or operation?

Authors:  C A Pellegrini; D Pohl
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

3.  Barrett's esophagus: is dysplasia a reliable marker in surveillance after endoscopic treatment?

Authors:  M A Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-10

4.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

5.  Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Authors:  M S Dar; J R Goldblum; T W Rice; G W Falk
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 6.  Barrett's esophagus: environmental influences in the progression of dysplasia.

Authors:  Ralph A Boulton; Bernhard Usselmann; Imtiyaz Mohammed; Janusz Jankowski
Journal:  World J Surg       Date:  2003-07-28       Impact factor: 3.352

Review 7.  High grade dysplasia: surveillance, mucosal ablation, or resection?

Authors:  Robert J Korst; Nasser K Altorki
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 8.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

9.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

10.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation.

Authors:  J F Fléjou; F Potet; F Muzeau; F Le Pelletier; F Fékété; D Hénin
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.